African Americans (AAs) and European Americans (EAs) differ in Alzheimer’s disease (AD) prevalence, risk factors, and symptomatic presentation and AAs are less likely to enroll in AD clinical trials.
African Americans (AAs) and European Americans (EAs) differ in Alzheimer’s disease (AD) prevalence, risk factors, and symptomatic presentation and AAs are less likely to enroll in AD clinical trials.